

Drug/Class	Effective Date	Overview	Posting Requirement for Notification to Providers
<u>9/4/2020</u> Reyvow	10/1/2020	Adding to formulary with PA	5 days
Nurtec ODT	10/1/2020	Adding to formulary with PA	5 days
Palforzia	10/1/2020	Adding to formulary with PA	5 days
Ayvakit	10/1/2020	Adding to formulary with PA	5 days
Tazverik	10/1/2020	Adding to formulary with PA	5 days
<u>8/24/2020</u> Oriahnn	10/1/2020	Adding to formulary with PA	5 days
Xpovio	10/1/2020	Adding indication to PA	5 days
Dupixent	10/1/2020	Age expansion to PA criteria	5 days
Zydelig	10/1/2020	Adding indication to PA	5 days
<u>7/27/2020</u> Orencia	8/1/2020	Double step removed; single step only required	5 days
<u>6/25/2020</u> Braftovi	8/1/2020	New indication added for colorectal cancer	5 days
Alunbrig	8/1/2020	Criteria updated to include 1st line therapy for ALK-positive metastatic NSCLC.	5 days
Zejula	8/1/2020	Criteria updated to include 1st line maintenance therapy for ovarian and related cancers	5 days
Lynparza	8/1/2020	Two new indications added for for 1st line in HRD+ ovarian and 2nd line in mCRPC	5 days
Rubraca	8/1/2020	New indication added for mCRPC with BRCA mutation following previous androgen/taxane-based chemotherapy	5 days
Imbruvica	8/1/2020	Adding indication for first line use in Waldenstrom Macroglobulinemia	5 days
<u>6/18/2020</u> Brukinsa	7/1/2020	Added to formulary with PA	5 days
Rozlytrek	7/1/2020	Added to formulary with PA	5 days
Pomalyst	7/1/2020	Added to formulary with PA	5 days

<u>6/11/2020</u> Endari	7/1/2020	Added to formulary with PA	5 days
Oxbryta	7/1/2020	Added to formulary with PA	5 days
SCIG	7/1/2020	Added to formulary with PA	5 days
Trikafta	7/1/2020	Added to formulary with PA	5 days
<u>5/15/2020</u> Ofev	06/18/2020	New Indication added to PA	5 days
<u>4/22/2020</u> Nerlynx	6/1/2020	New Indication added to PA	5 days
<u>3/11/2020</u> Clobetasol Formulations	5/1/2020	Removing PA	5 days
<u>3/03/2020</u> Nubeqa	4/1/2020	Adding to formulary with PA	5 days
Xtandi	6/1/2020	Removing from formulary ("Not Covered" & removing PA)	60 days
Erleada	6/1/2020	Removing from formulary, ("Not Covered" & removing PA)	60 days
Abiraterone	4/1/2020	Removing PA	5 days
Sunosi	4/1/2020	Adding to formulary with PA	5 days
Wakix	4/1/2020	Adding to formulary with PA	5 days
Xyrem	4/1/2020	Updating PA criteria to match class and included information on pediatric indication	5 days
Piqray	4/1/2020	Adding to formulary with PA	5 days
Vynda	4/1/2020	Adding to formulary with PA	5 days
Xpovio	4/1/2020	Adding to formulary with PA	5 days
Turalio	4/1/2020	Adding to formulary with PA	5 days
<u>2/13/2020</u> Imatinib	4/1/20	Removing PA	
Xifaxan 550 mg	5/1/20	New indication added to criteria - hepatic encephalopathy	
Sabril	4/1/20	Removing age restriction from all indications except for infantile spasms	

<u>1/31/2020</u> Bosentan/ ambrisentan	2/26/2020	Removing the PA and changing to a restriction to specialist (pulmonologist/cardiologist) edit	
Descovy	2/26/2020	PA criteria updated to include Pre-Exposure Prophylaxis of HIV infection	
Strensiq	3/24/2020	PA criteria updated to include required documentation criteria	
CGM	3/24/2020	The continuation criteria has been updated	
HCV drugs	2/26/2020	Updated PA Criteria	
Revlimid	2/26/2020	Removing the PA and changing to a restriction to specialist edit	
Trulance	4/1/2020	Adding PA for approved indications	
Motegrity	4/1/2020	Adding PA for approved indications	
Calquence	2/26/2020	PA criteria updated to remove step	
Lynparza	2/26/2020	PA criteria updated to add pancreatic cancer	
Adempas	2/26/2020	Adding additional step therapy to PA criteria	